Destroying senescent cells in the aging stem cell niche, either genetically or pharmacologically using the small-molecule senolytic ABT-263 (navitoclax; Abbvie Inc.), enhanced hippocampal neurogenesis and cognitive function in mice, a Canadian study led by scientists at the University of Toronto has found.

The enzyme poly [ADP-ribose] polymerase 1 (PARP1) is well known for its role in DNA damage repair, and multiple FDA-approved PARP inhibitors are used to treat BRCA-mutated tumors. Now, researchers at the Wistar Institute have described a role for PARP in regulating the genome of Epstein-Barr virus.

Investigators have identified structural differences between amyloid-beta (Abeta) aggregates in the postmortem brains of patients with inherited and sporadic Alzheimer's disease (AD), respectively. Moreover, both were different from the aggregates that form when Abeta assembles in vitro.

A study by researchers led by David James from the University of Sydney showcases the diversity in metabolic responses observed across different mouse strains exposed to two different diets that demonstrates the heritability of metabolic traits.

A team led by researchers from the ETH Zürich and the University of Basel has used a combination of mass spectrometry data and machine learning to predict antibiotic resistance of clinical bacterial samples. The results, which were published in the Jan. 10, 2022, issue of Nature Medicine, could speed the identification of optimal antibiotic regimens for patients.

By using data collected over decades in a database of more than 10 million active-duty military personnel, researchers have managed to nail down the connection between Epstein-Barr virus (EBV) infection and multiple sclerosis (MS).

LONDON – A population level study tracking every pregnancy in Scotland between the start of the pandemic in March 2020 and the end of October 2021 lays bare the devastating impact of COVID-19 on perinatal mortality.

Researchers at the Peter Doherty Institute for Infection and Immunity, the University of Queensland, Griffith University, the University of Adelaide and St. Jude Children's Research Hospital have unlocked a key to making existing front-line antibiotics work again against Streptococcus pneumoniae, the bacteria that cause pneumonia.

A number of possible mechanisms have been explored, but there is still no safe, reliable and universally applicable method for delivering drugs across the blood-brain barrier (BBB) to treat central nervous system diseases. Now researchers have succeeded in tuning the effect of methamphetamine, a cause of BBB breakdown, enabling brain penetration of small molecules and therapeutic proteins, without damaging the epithelial cells that constitute the main physical element of the barrier.

Clinicians at the University of Maryland have transplanted a heart from a genetically modified pig bred by Revivicor Inc., a subsidiary of United Therapeutics Corp., into a patient with end-stage heart failure.